1
Home
Companies

Kamada

#7121

Rank

$405.41M

Marketcap

IL Israel

Country

Kamada
Leadership team

Mr. Amir London (Chief Exec. Officer)

Mr. Chaime Orlev (Chief Financial Officer)

Mr. Eran Nir (Chief Operating Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Headquarters
Ness Ziona, HaMerkaz, Israel
Established
1990
Company Registration
SEC CIK number: 0001567529
Revenue
100M - 500M
Traded as
KMDA
Social Media
URL
https://www.kamada.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
History

Kamada was founded in 1990 by David Tzur, Ralph Hahn and Kamapharam Ltd., which was wholly owned by Kibbutz Beit Kama, until then Kamapharam was producing albumin, and its production facilities were acquired in full by Kamada In 1999, to a company owned by Hahn and another investor for $2.5 million. Hahn and Tzur headed the company by the beginning of 2013. The company completed its first public offering in 2005 on the Tel Aviv Stock Exchange.Today, the company specializes in the development, manufacture and marketing of proteins, especially for orphan diseases. The company produces about 10 injectable and marketed drugs in more than 15 countries around the world.Kamada is a member of the Biomed index on the Tel Aviv Stock Exchange, and as of December 2012, its shares were included in the Tel Aviv 100 index.In 2012, the company was ranked 456 among the 500 fastest growing companies in Europe according to the Deloitte Index, based on their income in 2007–2011.In May 2014, the company announced that it had not met the target set for the trial for a hereditary emphysema in inhalation. Following the failure of the experiment, the company's market value fell within a year from $500 million to $150 million.

Mission
To provide innovative medicines, developed and manufactured to the highest standards of safety, quality, and efficacy, that may improve outcomes and enhance patients’ lives.
Vision
To become a global leader in biopharmaceuticals by providing expanded access to convenient, cost-effective, and innovative therapies.
Key Team

Ms. Yifat Philip Esq. (VP of Legal, Gen. Counsel & Corp. Sec.)

Mr. David Tsur (Co-Founder & Deputy Chairman)

Ms. Hanni Neheman (VP of Marketing & Sales)

Ms. Ariella Raban (VP of HR)

Mr. Jon R. Knight (VP of US Commercial Operations)

Recognition and Awards
Kamada was awarded the ‘Innovative Israeli Company’ Award from the Israeli Prime Minister’s Office in 2019.
References

https://en.wikipedia.org/wiki/Kamada_(company)

https://www.investing.com/equities/kamada

https://finance.yahoo.com/quote/KMDA/profile?p=KMDA

https://www.crunchbase.com/organization/kamada

https://companiesmarketcap.com/

https://www.kamada.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Kamada
Leadership team

Mr. Amir London (Chief Exec. Officer)

Mr. Chaime Orlev (Chief Financial Officer)

Mr. Eran Nir (Chief Operating Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Headquarters
Ness Ziona, HaMerkaz, Israel
Established
1990
Company Registration
SEC CIK number: 0001567529
Revenue
100M - 500M
Traded as
KMDA
Social Media
URL
https://www.kamada.com